Single-dose azithromycin is recommended for treating Chlamydia trachomatis infections. Here, we established an in vitro cell model of azithromycin-induced persistent infection. Azithromycin inhibited the replication of C. trachomatis in a dose-time-dependent manner. Electron microscopy indicated that small inclusions in the induced model contained enlarged, aberrant and non-infectious reticulate bodies. RT-PCR showed that C. trachomatis still has the ability to express the unprocessed 16S rRNA gene in the model and that C. trachomatis recovered after the removal of azithromycin with a peak recovery time of 24 h. The mutations in 23S rRNA, L4 and L22 genes were not found in persistent infection, and qRT-PCR analysis showed that the relative expression level of euo in azithromycin treated infection was upregulated while omcB was downregulated. In summary, this study provides a novel in vitro cell model to examine the characteristics of azithromycin-induced persistent infection and contribute to the development of treatments for C. trachomatis infection.
INTRODUCTION
Chlamydia trachomatis infection is the most commonly reported sexually transmitted infection and over 100 million adults are infected each year globally (World Health Organization 2012) . In 2015, a total of 1526 658 C. trachomatis infections were reported in the USA (Centers for Disease Control and Prevention 2016). However, a symptomatic manifestation of urogenital chlamydial infection can only be observed in about 30% of the patients. In addition, C. trachomatis genital infection is often chronic in women, with symptoms ranging from mild infection to infertility and ectopic pregnancy (Menon et al. 2015; Peterman et al. 2015) . In recent years, persistence has become a central issue of chlamydial research. Chlamydia trachomatis is a Gram-negative, obligate intracellular bacterium that exists in at least two morphologically distinct forms: elementary bodies (EB) and reticulate bodies (RB). Environmentally stable EB infect host cells and differentiate into active, replicating RB within a membrane-bound vacuole called an inclusion. However, the classical biphasic cycle reflects only optimized growth conditions and needs to be extended to include persistence as a third state. The accepted definition of chlamydial persistence is defined by a reduced or absent production of infectious progeny EB, usually determined by subpassage infectious titer assay. Morphologically, this reversible state is characterized by aberrant bodies, specifically enlarged pleomorphic RB (Hogan et al. 2004; Schoborg 2011) . These aberrant bodies may remain within infected cells for lengthy periods and, upon removal of the persistence inducer, are reversible to yield infectious EBs.
Under exposure to certain adverse conditions, such as those imposed by IFN-γ , antibiotics or deprivation of nutrients, C. trachomatis can change to a status of persistent infection (Beatty, Byrne and Morrison 1993; Kintner et al. 2014) . IFN-γ -induced persistence has been well characterized. In one study, HeLa 229 cells were infected with C. trachomatis and treated with IFN-γ (Reveneau et al. 2005) . Electron microscopy disclosed small inclusions containing enlarged, aberrant and non-infectious RB. Removal of IFN-γ from the culture media allowed these RB to recover their normal form and continue to grow and differentiate into infectious EB. Nutrient restriction can also induce C. trachomatis persistence, and iron deprivation has been reported as a persistence inducer (Thompson and Carabeo 2011) . Penicillin is liable to induce persistent infections of C. trachomatis, as exposure to penicillin leads to enlarged and aberrant RB that resume normal growth after removal of penicillin (Ong et al. 1013) .
Although the induction of persistent C. trachomatis has been studied extensively in vitro, an azithromycin-induced persistence model remains undeveloped. Single-dose azithromycin has been recommended as the first-line antimicrobial regimen for genital C. trachomatis infection (Lanjouw et al. 2010; Centers for Disease Control and Prevention 2015) . A metaanalysis of chlamydia treatment reported that the cure rate for azithromycin was about 97% in 2002, but by 2014 this rate reduced to 94.3% (Lau and Qureshi 2002; Kong et al. 2014) . Another study (Kong et al. 2015) found that the random-effects pooled efficacy for azithromycin treatment was only about 82.9% for rectal infection. Treatment failure may lead to ongoing transmission (Peterman et al. 2015) , and the establishment of a cell model of azithromycin-induced persistence of C. trachomatis will be useful for greater understanding of treatment failure.
Our recent research has indicated that the susceptibility to azithromycin varied when it was added at different periods in the chlamydial life cycle. The minimal inhibitory concentration (MIC) of azithromycin began to increase at 8 h post infection and reached more than 125× at 24 h post infection (Zheng et al. 2015) . Based on this research, we investigated whether persistent infection could be induced by azithromycin. To establish a cell model of azithromycin-induced persistent C. trachomatis infection, we observed the characteristic morphological changes of aberrant RB. The viability of C. trachomatis was confirmed and infectious C. trachomatis recovered after removal of azithromycin. The persistent infection was not related to mutations of 23S rRNA, L4 or L22 protein genes (Misyurina et al. 2004; Jiang et al. 2015) . The expression of late genes in the C. trachomatis developmental cycle in azithromycin-treated cells indicated that RB-to -EB conversion was blocked.
MATERIAL AND METHODS

Chlamydial strain and cell culture
Chlamydia trachomatis serovar D and F were provided by Dr Joke Spaargaren of the Public Health Laboratory of the Municipal Health Service of Amsterdam, Netherlands. McCoy cells were grown in RPMI 1640 (Gibco, St. Louis, MO, USA) supplemented with 10% fetal calf serum, 0.02 M HEPES and 0.02% sodium bicarbonate at 37
• C in 5% CO 2 . Cells were seeded into TC24 culture plates as described previously (Zheng et al. 2015) . Monolayers were infected with C. trachomatis serovar F and centrifuged for 60 min at 1000 × g. After centrifugation, the supernatant was replaced with 1 mL of maintenance medium with 10% fetal calf serum and 1 μg/mL of cycloheximide (Sigma, St. Louis).After incubation for 72 h, the infected cells were harvested with sucrosephosphate glutamic acid buffer (SPG) and stored at -70 
Persistent chlamydial infection with azithromycin
McCoy cells grown in TC24 culture plates were inoculated with 1 × 10 5 IFU/mL of C. trachomatis serovar D or F in 0.25 mL of SPG and centrifuged for 1 h at 1000 × g. After centrifugation, the supernatant was replaced with 1 mL of the maintenance medium and the infected cells were cultured in the presence or absence of azithromycin. Differing concentrations of azithromycin in maintenance medium were added at 0, 6, 12, 18 and 24 h post infection. McCoy cells of the same culture dishes were treated as a negative control, and infected cells without azithromycin were treated as positive control. The number of inclusions per well in the different doses and at different time points was counted.
Chlamydial recovery
In order to measure the viability of C. trachomatis, the cultures were allowed to revert from persistence by the removal of azithromycin at 48 h post infection. After removing the azithromycin, phosphate-buffered saline (PBS) was used to wash the culture plate three times. The medium was replaced with an azithromycin-free medium. For each different azithromycin concentration, three wells of infected cells were collected 48 h post infection in SPG for determining infection C. trachomatis titer. After removal of azithromycin, the infected cells continued to culture for an additional 6, 12, 18 or 24 h for recovery. Cells were harvested in SPG at the different time points. The cells collected from the azithromycin-treated groups and the recovery groups were seeded to fresh McCoy cells. After culturing for 72 h, the number of inclusions in the recovery group was compared with those in the azithromycin-treated group. The optimal rescue time was determined by examining the recovery time course from 0 to 24 h and observing the peak number of inclusions.
Immunofluorescent staining
Infected McCoy cells from the culture monolayer were cultured on glass cover slips and fixed with methanol at 48 h after infection. Samples were incubated with FITC-conjugated monoclonal antibody against the C. trachomatis MOMP, and the IFU was counted. The number of inclusions per well was counted in 20 randomly selected fields under ×200 magnification. Chlamydia trachomatis inclusion morphology was observed by fluorescence microscopy (Olympus, Japan).
Electron microscopy
At 24 and 48 h post infection, the azithromycin-treated cells and the untreated cells were fixed with 10% glutaraldehyde in PBS (10 min, RT) and collected using a cell scraper. The cells were pelleted by centrifugation at 1000 × g for 5 min and stored at 4
• C.
The cell pellets were embedded and examined by transmission electron microscopy (TEM) (Olympus, Eindhoven, Netherlands) (Beatty, Byrne and Morrison 1993) . For the recovery group, the infected cells without azithromycin treatment were cultured for an additional 24 h and collected for TEM.
Viability testing by reverse transcription PCR
Azithromycin was added at 18 h post infection at concentrations of 0.08 or 0.16 μg/mL. Infected cells were washed twice with PBS and harvested at 24, 36 and 48 h post infection. RNA was isolated from McCoy cells infected with C. trachomatis in the presence or absence of azithromycin using TRI reagent (Sigma). About 1 μg total RNA was incubated with 200 U of murine leukemia virus reverse transcriptase (Life Technologies, Carlsbad, CA, USA). Amplification of cDNA was carried out in a total volume of 25 μL, using the primers of 16S rRNA gene and the unprocessed 16S rRNA gene of C. trachomatis. RT-PCR was performed as described by Gérard, Whittum-Hudson and Hudson (1997) . Amplification using the DS/P2us primer generated a 429-bp band corresponding to the unprocessed 16S rRNA. Amplification using DS/US2 primers generated a 363-bp band corresponding to the processed 16S rRNA. PCR products were visualized in agarose gels and stained with ethidium bromide.
PCR amplification and DNA sequencing of the macrolide resistance targets
PCR amplification and DNA sequencing were used to determine whether resistance to azithromycin was due to the mutation(s) in the 23S rRNA, rplD or rplV genes. Azithromycin was added to infected cells at 18 and 24 h post infection in concentrations of 0.16, 0.32 and 0.64 μg/mL. Cells were scraped at 48 h post infection and DNA was extracted using the Qiagen DNA isolation kit (Qiagen, Germany). The elution volume was 50 μL. Two primer sets, F1-R1 and F2-R2, were chosen for amplification of the C. trachomatis 23S rRNA gene and gave rise to amplicons of 285 or 526 bp, respectively. Forward primer F1 (5 -GCATTGAACCTAAGCCCTG-3 ), reverse primer R1 (5 -TGACTCCCACTCTCCTGAAG-3 ), forward primer F2 (5 -AGATGGACATTGCCAGACG -3 ) and reverse primer R2 (5 -TGCTTATCCTTTCCGAACG-3 ) were used to amplify part of the 23S rRNA gene. To detect changes in the L4 sequence, the 234-bp fragment was amplified using the forward primer L4F (5 -GGCTTAGGACCGAAAACAATC -3 ) and reverse primer L4R (5 -GAAGTTTGAATTGCCTGATGC-). To detect changes in the L22 sequence, the 255-bp fragment was amplified using the L22F forward primer (5 -GTTAGATGACTCGTGCGCTTC-3 ) and the L22R reverse primer (5 -AGCTGCAGGATTGATGAGAAA-3 ). Amplification was performed in a 9700 thermal cycler (Applied Biosystems, Waltham, MA, USA). Agarose gel was utilized for electrophoresis, and an ABI 310 Genetic Analyzer was used for detection. Sequence results were reviewed manually and compared with the NCBI BLAST software. The reference sequence of C. trachomatis serovar F was obtained from GenBank.
qRT-PCR analysis of early upstream ORF and omcB mRNA expression
Quantitative real-time PCR (qRT-PCR) was performed to measure the expression level of mRNA. Total RNA was extracted from McCoy cells after infection with C. trachomatis in the presence or absence of azithromycin. A first-strand cDNA synthesis kit was applied to produce cDNA, which were used as templates for qRT-PCR amplification. The omcB gene, encoding the chlamydial outer membrane complex protein B, was amplified with the forward primer (5 -GCAATGGTTTCTTACTGTGG -3 ) and reverse primer (5 -CAAGAAATTTGAGCTCCTGC -3 ). Furthermore, the forward primer (5 -TCCCCGACGCTCTCCTTTCA -3 ) and reverse primer (5 -CTCGTCAGGCTATCTATGTTGCT -3 ) were utilized to amplify early upstream ORF (euo) gene. 
Statistical analysis
GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA) was used for graphing data and data analysis performed using SPSS15.0 (SPSS Inc., Chicago, IL, USA). The quantitative data were presented as mean ± standard deviation (SD). Quantitative data for two groups were compared using the non-parametric test. Multiple groups of quantitative data were compared using two-way analysis of variance (ANOVA). Differences were considered significant at * P < 0.05, * * P < 0.01 and * * * P < 0.001.
RESULTS
Effect of azithromycin on the production of Chlamydia trachomatis inclusions
At 48 h post infection, inclusions were large and nearly round in the cells without azithromycin. However, inclusions were relatively small in the cells treated with azithromycin. Compared to normal infection conditions, the inclusions were smaller at 48 h post infection in the samples treated with azithromycin, at 18 h post infection, at concentrations of 0.08 or 0.16 μg/mL (Fig. 1) . Additionally, azithromycin inhibited the generation of C. trachomatis inclusions in a time-and dose-dependent manner when added to the cultures at 0, 6, 12, 18 and 24 h post infection. If azithromycin was added early, it inhibited the generation of C. trachomatis inclusions at low concentration. For instance, 0.08 μg/mL azithromycin completely inhibited the generation of C. trachomatis when added at 0 h post infection. However, C. trachomatis inclusions were still observed when azithromycin was added at 24 h post infection at concentration of 40 μg/mL (Table 1 ). The dose-dependent relationship was also observed when azithromycin was added at 18 h post infection. There were The effect of azithromycin on production of C. trachomatis was assessed at indicated times after infection. Azithromycin was added to the cultures at 0, 6, 12, 18 and 24 h post infection, respectively. The number of inclusions per well was calculated in 20 randomly selected ×200 microscopic fields. Data are presented as the mean of triplicate cultures ±SD of three independent experiments.
about 3620 inclusions at 0.08 μg/mL and 60 inclusions at 0.16 μg/mL per well.
Ultrastructural analysis of untreated and azithromycin-treated cells
Inclusions were analyzed by TEM at 24 and 48 h post infection (Fig. 2) . The typical RB and EB forms of inclusions were observed in untreated cells. Numerous small EB were evident in a large inclusion at 48 h post infection. Infected McCoy cells treated with 0.16 μg/mL azithromycin 18 h post infection contained a small inclusion with aberrant RB. After removal of azithromycin, the number of aberrant RB was decreased and the number of EB was increased (Fig. 2) .
Recovery of infectious Chlamydia trachomatis after removal of azithromycin
At 48 h post infection, the medium on the infected cells treated with azithromycin at 18 h post infection was replaced with azithromycin-free medium. The cells were harvested at 0, 6, 12, 18 and 24 h after removal of azithromycin. The collected cells were used to seed fresh McCoy cells, and the numbers of recovered EB from rescue times of 0, 6, 12, 18 and 24 h were counted (Table 2) . We found the infectious C. trachomatis recovered apparently at 24 h when the concentration of the azithromycin was 0.16 and 0.32 μg/mL (Fig. 3A) . After removal of azithromycin, ANOVA showed significant differences in the numbers of the recovered EB at the different time points (P < 0.05).
Viability testing by reverse transcription PCR
Unprocessed 16S rRNA is processed co-transcriptionally. Its presence indicated continued transcriptional activity and chlamydial viability. Our experiments revealed that unprocessed 16S rRNA and processed 16S rRNA continued to express after azithromycin treatment for 24 h. Thus, azithromycin treatment was not completely lethal to C. trachomatis in these experiments (Fig. 3B) .
No mutation of 23S rRNA gene, L4 or L22 protein gene in azithromycin-induced persistent infection
The 23S rRNA, rplD and rplV genes of C. trachomatis were sequenced from the samples of persistent infection treated with azithromycin at 18 and 24 h post infection. However, there were no mutations detected in these genes (Fig. 4A ).
Azithromycin-induced modulation of Euo and omcB genes suggests a delayed completion of the chlamydial life cycle
The qRT-PCR analysis showed significant upregulated expression of euo gene in azithromycin-treated cells as compared to normal infected cells. However, the relative expression level of omcB was significant downregulated in azithromycin-treated cells ( Fig. 4B and C) . Euo is an early gene of the chlamydial cycle and its protein can bind to the promoter region of the late gene omcB to regulate its expression (Rosario, Hanson and Tan 2014). The gene omcB was reported to be involved in the final stage of the life cycle (Fechtner et al. 2013) . The expression of omcB, which is associated with RB-to-EB conversion, was downregulated in this study.
DISCUSSION
Currently, azithromycin is recommended as the first-line antimicrobial for genital Chlamydia trachomatis infection. In this study, we established an in vitro persistent infection model of C. trachomatis induced by azithromycin in McCoy cells. Aberrant inclusions were observed, and the viability of C. trachomatis was confirmed by amplification of unprocessed 16S rRNA. Infectious C. trachomatis was recovered after removal of azithromycin. Moreover, we found that mutations of 23S rRNA, L4 and L22 genes were not relevant to persistent infection. The expression of the late gene omcB was decreased in azithromycintreated cells, indicating that RB-to-EB conversion was blocked.
To the best of our knowledge, this is the first cell model of C. trachomatis persistent infection induced by azithromycin. Chlamydial persistence is characterized by an incomplete developmental cycle and the formation of aberrant bodies (Wyrick 2010) . Demonstration of the aberrant formation through TEM is a means to prove persistent infection. These aberrant bodies have been found in C. trachomatis infected cultures treated with penicillin (Dille et al. 2014; Kintner et al. 2014) . Ultrastructural analysis revealed that the size of the RB became progressively larger with continued culture in the presence of the penicillin. Large abnormal RB forms were also confirmed in the presence of IFN-γ (Shima et al. 2013) . Our data also showed, under TEM, that aberrant bodies occurred in azithromycin-treated cells. Unprocessed 16S rRNA is extremely short lived and is found only in viable Chlamydia. The molecular approach based on RT-PCR of unprocessed 16S rRNA was first tried to demonstrate the viability of persistent non-cultivatable Chlamydia in patients with ectopic pregnancy or rheumatoid arthritis (Gérard, Whittum-Hudson and Hudson 1997) . To evaluate the impact of azithromycin on C. trachomatis viability, we further measured the expression of unprocessed 16S rRNA and processed 16S rRNA mRNA and found that there were still high expression levels in azithromycin-treated infected cells. Moreover, C. trachomatis recovered substantially 24 h after the removal of azithromycin. After removal of azithromycin, productive replication is an important feature for continued viability. These findings suggest that azithromycin plays a direct role in inducing C. trachomatis to enter a persistent state in the in vitro cell culture model. A small set of azithromycin concentrations were chosen to treat C. trachomatis-infected cells for different time points and the results demonstrated that azithromycin inhibited the production of C. trachomatis inclusions in a dose-time-dependent manner. Strikingly, the inhibition of the production of C. trachomatis is related to the dose of azithromycin. Previous studies suggested that a dose-dependent effect was observed in treatment with IFN-γ after infection. IFN-γ (0.05 ng/mL) had no effect on infection, while 2.0 ng/mL IFN-γ completely inhibited the production of infectious progeny (Beatty, Byrne and Morrison 1993) . Nevertheless, Reveneau et al. (2005) reported that IFN-γ -treated C. trachomatis exhibited aberrant inclusion formation at 0.01ng/mL and that doses from 0.05 to100 ng/mL did not significantly increase the numbers of aberrant inclusions. Interestingly, our results show that the ability of azithromucin to inhibit C. trachomatis was decreased when it was added at a longer time after onset of the infection. Low concentration of azithromycin could inhibit the production of C. trachomatis when it was added at an early time after infection. We propose that C. trachomatis patients may be cured with low concentrations of azithromycin when the C. trachomatis are only beginning to reproduce in the body. When a higher titer of C. trachomatis is found in the patients, the efficacy of a single 1 g dose of azithromycin for treatment is worth consideration. Moreover, our data would be interpreted that azithromycin does not inhibit viability of these preformed EBs once the EB is formed in the inclusion. This might explain why infectious progeny are present in this cell culture model. In a host, azithromycin is present for multiple days after the dose is taken. Consequently, EBs present at the time of drug administration might not be affected, but they would be affected when they infect a cell to carry out the next round of replication. In addition, it is not clear how long persistence can be maintained during azithromycin treatment. Therefore, experiments addressing this issue have potentially significant medical impacts.
Our research suggested that the azithromycin resistance in a persistent state was not related to mutations. Mutations in the 23S rRNA gene, L4 and L22 protein genes were not found in the azithromycin-induced persistence model. Mutations in the 23S rRNA have been mapped to the peptidyl transferase region, specifically A2057, A2058 or A2059 in the Escherichia coli numbering scheme. Mutations in Gln66 were reported in C. trachomatis L2 ribosomal protein L4, which corresponds to Gln 62 in the homologous E. coli protein (Binet and Maurelli 2007) . Suchland et al. (2005) reported that some rpoB mutations conferred very high levels of resistance to rifampin and the MIC of rifampin was up to 512 μg/mL. However, there were no mutations found when the MIC of azithromycin was 40 μg/mL in the persistent state. McCoy cells treated with azithromycin were collected at 48 h post infection for analysis of euo and omcB transcripts. Recovery groups were also collected and measured by qRT-PCR. The euo gene was upregulated (B) and omcB gene was downregulated (C). The results were from three independent experiments. Differences were considered significant at * P < 0.05, * * P < 0.01 and * * * P < 0.001.
The expression of late genes indicated that the RB-to-EB conversion was blocked in the persistent infection model. There are early, mid and late stages in the chlamydial developmental cycle. RB converting into EB occurs in the late stage. It has been reported that omcB gene is involved in the conversion of RB to EB and contributes to cell wall rigidity and osmotic stability of the EB (Mygind, Christiansen and Birkelund 1998; Hou et al. 2013) . The euo gene, encoding a DNA-binding protein, is a transcriptional repressor that prevents premature expression of σ 66-dependent late genes until late in the developmental cycle Tan 2012, 2016) . Belland et al. (2003) reported that one feature of chlamydial persistence is that late gene expression is downregulated when Chlamydia-infected cells are treated with IFN-γ . At the same time, euo is dramatically upregulated during persistence. Both euo and omcB are differentially expressed in active and IFNγ -driven persistent growth, which is consistent with other persistence inducers, suggesting that the utility of choosing euo/omcB expression ratio as a putative biomarker of in vivo growth. By calculating the ratio of euo to omcB mRNA, Lewis et al. (2014) found that two patients described in their study had contrasting patterns of chlamydial growth. Interestingly, our azithromycin-induced persistent infection cell model produced the same results as in Belland's study. Our findings suggest that high level of euo may be relevant to the repression of late genes during cell culture persistence. However, the mechanism of how the expression of euo is regulated during chlamydial persistence remains to be elucidated.
One limitation of this study is that the cell culture model cannot replace animal models or the analysis of human tissues. However, the cell culture model provides a convenient vehicle allowing researchers to study the mechanisms in persistent C. trachomatis infections. To elucidate the interaction between Chlamydia and host cells, further research should compare the transcriptomic profiles of persistently infected cells and cells from an acute infection. The genes encoding important functional proteins are potential drug targets for the treatment of persistent C. trachomatis infections. In conclusion, this study highlights the potential for using azithromycin to induce persistent C. trachomatis infections in an in vitro cell model, which could be important for understanding the mechanisms of persistent infection. However, our initial findings should be further expanded in more comprehensive and more detailed studies.
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